Literature DB >> 22132847

Primary orbital extraskeletal osteosarcoma.

Jennifer C Fan1, Duncan L Lamont, Adam R Greenbaum, Stephen G J Ng.   

Abstract

The authors describe a case of orbital extraskeletal osteosarcoma. A 78-year-old man with a history of rheumatoid arthritis on long-term corticosteroids had a left medial canthal basal cell carcinoma excision followed by adjuvant radiotherapy. Twelve months later, he re-presented with a large rapidly-growing calcified mass involving his left medial canthus and orbit. An incisional biopsy demonstrated an infiltrate of atypical cells exhibiting mitotic activity with a rosette arrangement around partially calcified necrotic tissue. The patient underwent orbital exenteration and a partial maxillectomy. Histopathology demonstrated an extraskeletal osteosarcoma. It is extremely rare for this tumor to occur in the orbit. Immunosuppression and adjuvant radiotherapy were possible predisposing factors in the development of this tumor. Extraskeletal osteosarcoma (ESOS) is a malignant tumour that produces osteoid. It develops in soft tissue without continuity to bone or periosteum. It is rare and comprises fewer than 5% of all osteosarcomas. Extraskeletal osteosarcoma primarily affects patients above 50 years of age and has a poor prognosis. In this report, we describe the clinical, radiologic, and pathologic records of a rare case of primary ESOS of the orbit.

Entities:  

Mesh:

Year:  2011        PMID: 22132847     DOI: 10.3109/01676830.2011.602170

Source DB:  PubMed          Journal:  Orbit        ISSN: 0167-6830


  2 in total

1.  Primary Extraskeletal Osteosarcoma Arising from the Optic Nerve: A Rare Case Report.

Authors:  Bifica Lyngdoh; Jaya Mishra; Biswajit Dey; Caleb Harris; Arindom Kakati; Zachariah Chowdhury; Rintu Marak; Evarisalin Marbaniang
Journal:  Ocul Oncol Pathol       Date:  2018-02-14

Review 2.  Primary orbital extraskeletal osteosarcoma and review of literature.

Authors:  Jingwen Hui; Yun Zhao; Lei Zhang; Jinyong Lin; Hong Zhao
Journal:  BMC Ophthalmol       Date:  2020-10-22       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.